InvestorsHub Logo
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: None

Friday, 05/19/2017 9:27:19 AM

Friday, May 19, 2017 9:27:19 AM

Post# of 660
and another buy rating with tgt $14

https://thefly.com/landingPageNews.php?id=2555207&headline=AXSM-Axsome-Therapeutics-initiated-with-a-Buy-at-BTIG

Axsome Therapeutics initiated with a Buy at BTIG BTIG analyst Robert Hazlett started coverage of Axsome with a $14 price target and a Buy rating. The analyst says that the company's AXS-05 combination is unique and could treat a number of disorders. He notes that data on the combination's impact on treatment-resistant depression is due in early 2018. Tgh analyst adds that the company's AXS-02 drug "is a novel approach to the treatment of pain," and reports that data on the drug is due out in Q3 and Q4.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXSM News